VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01891708

Enrollment

Registered

2013-07-03

Start date

2013-06-30

Completion date

2018-12-31

Last updated

2013-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Metastasis, Non Small Cell Lung Cancer

Brief summary

a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Detailed description

1. non small cell lung cancer (non squamous carcinoma) 2. ECOG 0-1 3. from 18-75 years old

Interventions

OTHERbevacizumab, standard chemotherapy and radiation

the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* non squamous cell non small cell lung cancer * with measurable disease * ECOG 0-1

Exclusion criteria

\- patients received surgery in recent 4 weeks

Design outcomes

Primary

Measure	Time frame
PFS	6 months

Secondary

Measure	Time frame
OS	18 months

Countries

China

Contacts

Primary ContactLi Liu, MD

liulixiehe@163.com027-85872015

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026